Label: ANTIROBE- clindamycin hydrochloride capsule 

  • NDC Code(s): 0009-3043-01, 0009-3044-01, 0009-3045-01, 0009-3045-08, view more
    0009-5015-01
  • Packager: Pharmacia and Upjohn Company
  • Category: PRESCRIPTION ANIMAL DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: New Animal Drug Application

Drug Label Information

Updated 05/10

If you are a consumer or patient please visit this version.

  • SPL UNCLASSIFIED SECTION

    Caution: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

    Close
  • DESCRIPTION

    ANTIROBE Capsules and ANTIROBE AQUADROPS Liquid contain clindamycin hydrochloride which is the hydrated salt of clindamycin. Clindamycin is a semisynthetic antibiotic produced by a 7(S)-chlorosubstitution of the 7(R)-hydroxyl group of a naturally produced antibiotic produced by Streptomyces lincolnensis var. lincolnensis.

    ANTIROBE Capsules (For Use in Dogs Only):

    25 mg Capsule, each yellow and white capsule contains clindamycin hydrochloride equivalent to 25 mg of clindamycin.

    75 mg Capsule, each green capsule contains clindamycin hydrochloride equivalent to 75 mg of clindamycin.

    150 mg Capsule, each light blue and green capsule contains clindamycin hydrochloride equivalent to 150 mg of clindamycin.

    300 mg Capsule, each light blue capsule contains clindamycin hydrochloride equivalent to 300 mg of clindamycin.

    ANTIROBE AQUADROPS Liquid (For Use in Dogs and Cats) is a palatable formulation intended for oral administration. Each mL of ANTIROBE AQUADROPS Liquid contains clindamycin hydrochloride equivalent to 25 mg clindamycin; and ethyl alcohol, 8.64%.

    Close
  • CLINICAL PHARMACOLOGY

    Absorption

    Clindamycin hydrochloride is rapidly absorbed from the canine and feline gastrointestinal tract.

    Dog Serum Levels

    Serum levels at or above 0.5 µg/mL can be maintained by oral dosing at a rate of 2.5 mg/lb of clindamycin hydrochloride every 12 hours. This same study revealed that average peak serum concentrations of clindamycin occur 1 hour and 15 minutes after oral dosing. The elimination half-life for clindamycin in dog serum was approximately 5 hours. There was no bioactivity accumulation after a regimen of multiple oral doses in healthy dogs.

    Clindamycin Serum Concentrations
    2.5 mg/lb (5.5 mg/kg) After B.I.D. Oral
    Dose of Antirobe Capsules to Dogs
    Chemical Structure

    Cat Serum Levels

    Serum levels at or above 0.5 μg/mL can be maintained by oral dosing at a rate of 5 mg/lb of clindamycin hydrochloride liquid every 24 hours. The average peak serum concentration of clindamycin occurs approximately 1 hour after oral dosing. The elimination half-life of clindamycin in feline serum is approximately 7.5 hours. In healthy cats, minimal accumulation occurs after multiple oral doses of clindamycin hydrochloride, and steady-state should be achieved by the third dose.

    Clindamycin Serum Concentrations
    5 mg/lb (11 mg/kg) After Single Oral
    Dose of Antirobe Aquadrops to Cats
    Chemical Structure

    Metabolism and Excretion

    Extensive studies of the metabolism and excretion of clindamycin hydrochloride administered orally in animals and humans have shown that unchanged drug and bioactive and bioinactive metabolites are excreted in urine and feces. Almost all of the bioactivity detected in serum after ANTIROBE product administration is due to the parent molecule (clindamycin). Urine bioactivity, however, reflects a mixture of clindamycin and active metabolites, especially N-demethyl clindamycin and clindamycin sulfoxide.

    Site and Mode of Action

    Clindamycin is an inhibitor of protein synthesis in the bacterial cell. The site of binding appears to be in the 5OS sub-unit of the ribosome. Binding occurs to the soluble RNA fraction of certain ribosomes, thereby inhibiting the binding of amino acids to those ribosomes. Clindamycin differs from cell wall inhibitors in that it causes irreversible modification of the protein-synthesizing subcellular elements at the ribosomal level.

    Microbiology

    Clindamycin is a lincosaminide antimicrobial agent with activity against a wide variety of aerobic and anaerobic bacterial pathogens. Clindamycin is a bacteriostatic compound that inhibits bacterial protein synthesis by binding to the 5OS ribosomal sub-unit. The minimum inhibitory concentrations (MICs) of Gram-positive and obligate anaerobic pathogens isolated from dogs and cats in the United States are presented in Table 1 and Table 2. Bacteria were isolated in 1998-1999. All MICs were performed in accordance with the Clinical and Laboratory Standards Institute (CLSI).

    Table 1. Clindamycin MIC Values (μg/mL) from Diagnostic Laboratory Survey Data Evaluating Canine Pathogens in the U.S. during 1998-99*
    Organism Number
    of
    Isolates
    MIC50 MIC85 MIC90 Range
    *
    The correlation between the in vitro susceptibility data and clinical response has not been determined.
    Soft Tissue/Wound: includes samples labeled wound, abscess, aspirate, exudates, draining tract, lesion, and mass
    Osteomyelitis/Bone: includes samples labeled bone, fracture, joint, tendon
    §
    No range, all isolates yielded the same value
    Dermal/Skin: includes samples labeled skin, skin swab, biopsy, incision, lip
    Soft Tissue/Wound
     Staphylococcus
      aureus
    17 0.5 0.5 ≥4.0 0.25-≥4.0
     Staphylococcus
      intermedius
    28 0.25 0.5 ≥4.0 0.125-≥4.0
     Staphylococcus
      spp.
    18 0.5 0.5 ≥4.0 0.25-≥4.0
     Beta-hemolytic
      streptococci
    46 0.5 0.5 ≥4.0 0.25-≥4.0
     Streptococcus
      spp.
    11 0.5 ≥4.0 ≥4.0 0.25-≥4.0
    Osteomyelitis/Bone
     Staphylococcus
      aureus
    20 0.5 0.5 0.5 0.5§
     Staphylococcus
      intermedius
    15 0.5 ≥4.0 ≥4.0 0.25-≥4.0
     Staphylococcus
      spp.
    18 0.5 ≥4.0 ≥4.0 0.25-≥4.0
     Beta-hemolytic
      streptococci
    21 0.5 2.0 2.0 0.25-≥4.0
     Streptococcus
      spp.
    21 ≥4.0 ≥4.0 ≥4.0 0.25-≥4.0
    Dermal/Skin
     Staphylococcus
      aureus
    25 0.5 ≥4.0 ≥4.0 0.25-≥4.0
     Staphylococcus
      intermedius
    48 0.5 ≥4.0 ≥4.0 0.125-≥4.0
     Staphylococcus
      spp.
    32 0.5 ≥4.0 ≥4.0 0.25-≥4.0
     Beta-hemolytic
      streptococci
    17 0.5 0.5 0.5 0.25-0.5
    Table 2. Clindamycin MIC Values (µg/mL) from Diagnostic Laboratory Survey Data Evaluating Feline Pathogens from Wound and Abscess Samples in the U.S. during 1998*
    Organism Number
    of
    Isolates
    MIC50 MIC90 Range
    *
    The correlation between the in vitro susceptibility data and clinical response has not been determined.
    Bacteroides/
    Prevotella
    30 0.06 4.0 ≤0.015-4.0
    Fusobacterium
    spp.
    17 0.25 0.25 ≤0.015-0.5
    Peptostreptococcus
    spp.
    18 0.13 0.5 ≤0.015-8.0
    Porphyromonas
    spp.
    13 0.06 0.25 ≤0.015-8.0
    Close
  • INDICATIONS

    ANTIROBE (brand of clindamycin hydrochloride) Capsules (for use in dogs only) and AQUADROPS Liquid (for use in dogs and cats) are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below:

    Dogs: Skin infections (wounds and abscesses) due to coagulase positive staphylococci (Staphylococcus aureus or Staphylococcus intermedius). Deep wounds and abscesses due to Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum and Clostridium perfringens.

    Dental infections due to Staphylococcus aureus, Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum and Clostridium perfringens. Osteomyelitis due to Staphylococcus aureus, Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum and Clostridium perfringens.

    Cats: Skin infections (wounds and abscesses) due to Staphylococcus aureus, Staphylococcus intermedius, Streptococcus spp. Deep wounds and infections due to Clostridium perfringens and Bacteroides fragilis.

    Dental infections due to Staphylococcus aureus, Staphylococcus intermedius, Streptococcus spp., Clostridium perfringens and Bacteroides fragilis.

    Close
  • CONTRAINDICATIONS

    ANTIROBE Capsules and ANTIROBE AQUADROPS Liquid are contraindicated in animals with a history of hypersensitivity to preparations containing clindamycin or lincomycin.

    Because of potential adverse gastrointestinal effects, do not administer to rabbits, hamsters, guinea pigs, horses, chinchillas or ruminating animals.

    Close
  • WARNINGS

    Keep out of reach of children. Not for human use.

    Close
  • PRECAUTIONS

    During prolonged therapy of one month or greater, periodic liver and kidney function tests and blood counts should be performed.

    The use of ANTIROBE occasionally results in overgrowth of non-susceptible organisms such as clostridia and yeasts. Therefore, the administration of ANTIROBE should be avoided in those species sensitive to the gastrointestinal effects of clindamycin (see CONTRAINDICATIONS). Should superinfections occur, appropriate measures should be taken as indicated by the clinical situation.

    Patients with very severe renal disease and/or very severe hepatic disease accompanied by severe metabolic aberrations should be dosed with caution, and serum clindamycin levels monitored during high-dose therapy.

    Clindamycin hydrochloride has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore, ANTIROBE should be used with caution in animals receiving such agents.

    Safety in gestating bitches and queens or breeding male dogs and cats has not been established.

    Close
  • ADVERSE REACTIONS

    Side effects occasionally observed in either clinical trials or during clinical use were vomiting and diarrhea.

    To report a suspected adverse reaction call 1-800-366-5288.

    Close
  • DOSAGE AND ADMINISTRATION

    Dogs

    Infected Wounds, Abscesses, and Dental Infections

    Oral

    2.5-15.0 mg/lb body weight every 12 hours.

    Duration

    Treatment with ANTIROBE products may be continued up to a maximum of 28 days if clinical judgment indicates. Treatment of acute infections should not be continued for more than three or four days if no response to therapy is seen.

    Dosage Schedule

    Capsules

    ANTIROBE 25 mg, administer 1-6 capsules every 12 hours for each 10 pounds of body weight.

    ANTIROBE 75 mg, administer 1-6 capsules every 12 hours for each 30 pounds of body weight.

    ANTIROBE 150 mg, administer 1-6 capsules every 12 hours for each 60 pounds of body weight.

    ANTIROBE 300 mg, administer 1-6 capsules every 12 hours for each 120 pounds of body weight.

    Liquid

    ANTIROBE AQUADROPS, administer 1-6 mL/10 lbs body weight every 12 hours.

    Dogs

    Osteomyelitis

    Oral

    5.0-15.0 mg/lb body weight every 12 hours.

    Duration

    Treatment with ANTIROBE is recommended for a minimum of 28 days. Treatment should not be continued for longer than 28 days if no response to therapy is seen.

    Dosage Schedule

    Capsules

    ANTIROBE 25 mg, administer 2-6 capsules every 12 hours for each 10 pounds of body weight.

    ANTIROBE 75 mg, administer 2-6 capsules every 12 hours for each 30 pounds of body weight.

    ANTIROBE 150 mg, administer 2-6 capsules every 12 hours for each 60 pounds of body weight.

    ANTIROBE 300 mg, administer 2-6 capsules every 12 hours for each 120 pounds of body weight.

    Liquid

    ANTIROBE AQUADROPS, administer 2-6 mL/10 lbs body weight every 12 hours.

    Cats

    Infected Wounds, Abscesses, and Dental Infections

    5.0 - 15.0 mg/lb body weight once every 24 hours depending on the severity of the condition.

    Duration

    Treatment with ANTIROBE AQUADROPS Liquid may be continued up to a maximum of 14 days if clinical judgment indicates. Treatment of acute infections should not be continued for more than three to four days if no clinical response to therapy is seen.

    Dosage Schedule

    ANTIROBE AQUADROPS, to provide 5.0 mg/lb, administer 1 mL/5 lbs body weight once every 24 hours; to provide 15.0 mg/lb, administer 3 mL/5 lbs body weight once every 24 hours.

    Close
  • ANIMAL SAFETY SUMMARY

    Rat and Dog Data

    One year oral toxicity studies in rats and dogs at doses of 30, 100 and 300 mg/kg/day (13.6, 45.5 and 136.4 mg/lb/day) have shown clindamycin hydrochloride capsules to be well tolerated. Differences did not occur in the parameters evaluated to assess toxicity when comparing groups of treated animals with contemporary controls. Rats administered clindamycin hydrochloride at 600 mg/kg/day (272.7 mg/lb/day) for six months tolerated the drug well; however, dogs orally dosed at 600 mg/kg/day (272.7 mg/lb/day) vomited, had anorexia, and subsequently lost weight. At necropsy these dogs had erosive gastritis and focal areas of necrosis of the mucosa of the gallbladder.

    Safety in gestating bitches or breeding males has not been established.

    Cat Data

    The recommended daily therapeutic dose range for clindamycin hydrochloride (ANTIROBE AQUADROPS Liquid) is 11 to 33 mg/kg/day (5 to 15 mg/lb/day) depending on the severity of the condition. Clindamycin hydrochloride (ANTIROBE AQUADROPS Liquid) was tolerated with little evidence of toxicity in domestic shorthair cats when administered orally at 10X the minimum recommended therapeutic daily dose (11 mg/kg; 5 mg/lb) for 15 days, and at doses up to 5X the minimum recommended therapeutic dose for 42 days. Gastrointestinal tract upset (soft feces to diarrhea) occurred in control and treated cats with emesis occurring at doses 3X or greater than the minimum recommended therapeutic dose (11 mg/kg/day; 5 mg/lb/day). Lymphocytic inflammation of the gallbladder was noted in a greater number of treated cats at the 110 mg/kg/day (50 mg/lb/day) dose level than for control cats. No other effects were noted. Safety in gestating queens or breeding male cats has not been established.

    Close
  • STORAGE

    Store at controlled room temperature 20° to 25°C (68° to 77°F).

    Close
  • HOW SUPPLIED

    ANTIROBE Capsules are available as:

     
    25 mg - bottles of 600
     
    75 mg - bottles of 200
     
    150 mg - bottles of 100
     
    150 mg - blister packages of 100
     
    300 mg - blister packages of 100
     
    NADA #120–161, Approved by FDA

    ANTIROBE AQUADROPS Liquid is available as 20 mL filled in 30 mL bottles (25 mg/mL) supplied in packers containing 12 cartoned bottles with direction labels and calibrated dosing droppers.

    NADA #135–940, Approved by FDA

    To request a material safety data sheet (MSDS), call 1-800-733-5500.

    ANTIROBE AQUADROPS

    Distributed by:
    Pharmacia & Upjohn Company
    Division of Pfizer Inc
    New York, NY 10017

    ANTIROBE Capsules

    Made in Canada

    Distributed by:
    Pharmacia & Upjohn Company
    Division of Pfizer Inc
    New York, NY 10017

    Revised March 2010

    11104900

    Close
  • PRINCIPAL DISPLAY PANEL - 25 mg Capsule Bottle Label

    600 Capsules

    Antirobe®
    clindamycin hydrochloride
    capsules, USP

    25 mg

    Equiv. to 25 mg clindamycin

    For Use in Dogs Only

    Caution: Federal (USA) law
    restricts this drug to use by or on
    the order of a licensed
    veterinarian.

    NADA #120-161, Approved by FDA

    Pfizer

    PRINCIPAL DISPLAY PANEL - 25 mg Capsule Bottle Label
    Close
  • PRINCIPAL DISPLAY PANEL - 75 mg Capsule Bottle Label

    200 Capsules

    Antirobe®
    clindamycin hydrochloride
    capsules, USP

    75 mg

    Equiv. to 75 mg clindamycin

    For Use in Dogs Only

    Caution: Federal (USA) law
    restricts this drug to use by or on
    the order of a licensed
    veterinarian.

    NADA #120-161, Approved by FDA

    Pfizer

    PRINCIPAL DISPLAY PANEL - 75 mg Capsule Bottle Label
    Close
  • PRINCIPAL DISPLAY PANEL - 150 mg Capsule Bottle Label

    100 Capsules

    Antirobe®
    clindamycin hydrochloride
    capsules, USP

    150 mg

    Equiv. to 150 mg clindamycin

    For Use in Dogs Only

    Caution: Federal (USA) law
    restricts this drug to use by or on the order of a licensed veterinarian.

    NADA #120-161, Approved by FDA

    Pfizer

    PRINCIPAL DISPLAY PANEL - 150 mg Capsule Bottle Label
    Close
  • PRINCIPAL DISPLAY PANEL - 300 mg Capsule Bottle Label

    ANTIROBE™
    Capsules

    clindamycin hydrochloride capsules, USP

    300 mg

    Equivalent to 300 mg clindamycin
    For Use In Dogs Only

    Caution: Federal (USA) law restricts this drug to
    use by or on the order of a licensed veterinarian.

    NADA # 120-161 Approved by FDA

    Pharmacia
    & Upjohn

    PRINCIPAL DISPLAY PANEL - 300 mg Capsule Bottle Label
    Close
  • INGREDIENTS AND APPEARANCE
    ANTIROBE 
    clindamycin hydrochloride capsule
    Product Information
    Product Type PRESCRIPTION ANIMAL DRUG LABEL Item Code (Source) NDC:0009-3043
    Route of Administration ORAL DEA Schedule     
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    clindamycin hydrochloride (clindamycin) clindamycin hydrochloride 25 mg
    Product Characteristics
    Color YELLOW, WHITE Score no score
    Shape CAPSULE Size 16mm
    Flavor Imprint Code ANTIROBE;25;MG
    Contains     
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:0009-3043-01 600 in 1 BOTTLE, PLASTIC
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    NADA NADA120161 05/31/1984
    ANTIROBE 
    clindamycin hydrochloride capsule
    Product Information
    Product Type PRESCRIPTION ANIMAL DRUG LABEL Item Code (Source) NDC:0009-3044
    Route of Administration ORAL DEA Schedule     
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    clindamycin hydrochloride (clindamycin) clindamycin hydrochloride 75 mg
    Product Characteristics
    Color GREEN Score no score
    Shape CAPSULE Size 16mm
    Flavor Imprint Code ANTIROBE;75;MG
    Contains     
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:0009-3044-01 200 in 1 BOTTLE, PLASTIC
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    NADA NADA120161 05/31/1984
    ANTIROBE 
    clindamycin hydrochloride capsule
    Product Information
    Product Type PRESCRIPTION ANIMAL DRUG LABEL Item Code (Source) NDC:0009-3045
    Route of Administration ORAL DEA Schedule     
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    clindamycin hydrochloride (clindamycin) clindamycin hydrochloride 150 mg
    Product Characteristics
    Color BLUE (light blue) , GREEN Score no score
    Shape CAPSULE Size 20mm
    Flavor Imprint Code ANTIROBE;150;MG
    Contains     
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:0009-3045-01 100 in 1 BOTTLE, PLASTIC
    2 NDC:0009-3045-08 100 in 1 BLISTER PACK
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    NADA NADA120161 05/31/1984
    ANTIROBE 
    clindamycin hydrochloride capsule
    Product Information
    Product Type PRESCRIPTION ANIMAL DRUG LABEL Item Code (Source) NDC:0009-5015
    Route of Administration ORAL DEA Schedule     
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    clindamycin hydrochloride (clindamycin) clindamycin hydrochloride 300 mg
    Product Characteristics
    Color BLUE (Light Blue) Score no score
    Shape CAPSULE Size 22mm
    Flavor Imprint Code ANTIROBE;300;MG
    Contains     
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:0009-5015-01 100 in 1 BLISTER PACK
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    NADA NADA120161 05/31/1984 05/18/2010
    Labeler - Pharmacia and Upjohn Company (829076566)
    Establishment
    Name Address ID/FEI Business Operations
    Patheon Whitby Inc. 205475333 MANUFACTURE
    Establishment
    Name Address ID/FEI Business Operations
    Patheon Inc., Toronto Region Operations 243790024 MANUFACTURE
    Close